SCHEMBL597128

SCHEMBL597128

NNCc1ccccc1F

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.55
TAAR1 Q96RJ0 2/20 0.54
IDO1 P14902 3/20 0.50
KMT2A Q03164 3/20 0.50
MEN1 O00255 2/20 0.50
ALDH1A1 P00352 2/20 0.48
CYP1A2 P05177 2/20 0.48
CYP2C9 P11712 2/20 0.48
CYP2C19 P33261 2/20 0.48
L3MBTL1 Q9Y468 2/20 0.48
HPGD P15428 1/20 0.48
MAPT P10636 3/20 0.48
GAA P10253 1/20 0.48
MPO P05164 2/20 0.47
CA1 P00915 1/20 0.46
CA2 P00918 1/20 0.46
CYP3A4 P08684 2/20 0.46
ATM Q13315 1/20 0.46
PLA2G1B P04054 1/20 0.46
CYP2D6 P10635 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL4886061 0.98 LMNA (0.53) LMNATAAR1IDO1KMT2AMEN1
Hydrochloric Acid SCHEMBL5074839 0.98 LMNA (0.53) LMNATAAR1IDO1KMT2AMEN1
SCHEMBL6068499 0.82 MAPT (0.41) LMNATAAR1IDO1KMT2AMEN1
Hydrochloric Acid SCHEMBL16796409 0.80 MAPT (0.44) LMNATAAR1IDO1KMT2AALDH1A1
SCHEMBL6071681 0.80 MPO (0.60) LMNATAAR1KMT2AMEN1ALDH1A1
SCHEMBL28460945 0.79 ALDH1A1 (0.39) LMNATAAR1IDO1KMT2AMEN1
SCHEMBL25588006 0.78 LMNA (0.57) LMNATAAR1IDO1KMT2AMEN1
SCHEMBL27565797 0.77 TAAR1 (0.64) LMNATAAR1IDO1KMT2AMEN1
SCHEMBL9734517 0.77 LMNA (0.54) LMNAKMT2AMEN1ALDH1A1HPGD
SCHEMBL30659219 0.77 LMNA (0.54) LMNAKMT2AMEN1ALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 356 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-120118085-A Preparation method of Milvexian 中国药科大学 2025-06-10 CN claimed
CN-116239593-B Preparation method of vitamin Li Xigu intermediate 上海裕兰生物科技有限公司 2025-05-02 CN claimed
CN-116239593-A Preparation method of vitamin Li Xigu intermediate 上海裕兰生物科技有限公司 2023-06-09 CN claimed
US-20260103457-A1 NOVEL PROCESS FOR PREPARATION OF SOLUBLE GUANYLATE CYCLASE STIMULATORS CYCLERION THERAPEUTICS INC (US) 2026-04-16 US disclosed
EP-1506193-B9 CARBAMATE-SUBSTITUTED PYRAZOLOPYRIDINES ADVERIO PHARMA GMBH (DE) 2026-02-18 EP disclosed
EP-1506193-B3 CARBAMATE-SUBSTITUTED PYRAZOLOPYRIDINES ADVERIO PHARMA GMBH (DE) 2025-12-03 EP disclosed
US-20250361228-A1 PROCESSES AND INTERMEDIATES FOR THE PREPARATION OF SOLUBLE GUANYLATE CYCLASE STIMULATORS CYCLERION THERAPEUTICS INC (US) 2025-11-27 US disclosed
US-20250255821-A1 SOLID DISPERSIONS COMPRISING A SGC STIMULATOR CYCLERION THERAPEUTICS, INC. 2025-08-14 US disclosed
EP-4570797-A2 NOVEL PROCESSES AND INTERMEDIATES FOR THE PREPARATION OF SOLUBLE GUANYLATE CYCLASE STIMULATORS Cyclerion Therapeutics, Inc. (US) 2025-06-18 EP disclosed
CN-116239593-B Preparation method of vitamin Li Xigu intermediate 上海裕兰生物科技有限公司 2025-05-02 CN disclosed
CN-116239593-B Preparation method of vitamin Li Xigu intermediate 上海裕兰生物科技有限公司 2025-05-02 CN disclosed
WO-2000066582-A1 SUBSTITUTED PYRAZOLE DERIVATIVE BAYER AKTIENGESELLSCHAFT (DE) 2000-11-09 WO disclosed
WO-2000006568-A1 SUBSTITUTED PYRAZOLE DERIVATIVES BAYER AKTIENGESELLSCHAFT (DE) 2000-02-10 WO disclosed
WO-2000006569-A1 SUBSTITUTED PYRAZOLE DERIVATIVES CONDENSED WITH SIX-MEMBERED HETEROCYCLIC RINGS BAYER AKTIENGESELLSCHAFT (DE) 2000-02-10 WO disclosed
WO-2000006567-A1 3-(4-AMINO-5-ETHYLPYRIMIDINE-2-YL)-1-(2-FLUOROBENZYL)-1H-PYRAZOLO[3,4-B]PYRIDINE BAYER AKTIENGESELLSCHAFT (DE) 2000-02-10 WO disclosed
EP-0248466-B1 PESTICIDAL TETRAZINE DERIVATIVES SHELL INTERNATIONALE RESEARCHMAATSCHAPPIJ B.V. (NL) 1990-10-31 EP disclosed
EP-0248466-A2 Pesticidal tetrazine derivatives SHELL INTERNATIONALE RESEARCHMAATSCHAPPIJ B.V. (NL) 1987-12-09 EP disclosed
US-4076943-A DIURETICS, SALURETICS, ANTIHYPERTENSIVES BAYER AKTIENGESELLSCHAFT (DT) 1978-02-28 US disclosed
US-4061653-A DIURETIC, SALURETIC, ANTIHYPERTENSIVE BAYER AKTIENGESELLSCHAFT (DT) 1977-12-06 US disclosed
US-3950528-A HYPOTENSIVE AGENTS, SALURETICS, DIURETICS BAYER AKTIENGESELLSCHAFT (DT) 1976-04-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250361228-A1 PROCESSES AND INTERMEDIATES FOR THE PREPARATION OF SOLUBLE GUANYLATE CYCLASE STIMULATORS GUCY1A2, GUCY1B1, GUCY1B2 LMNA 2860/4885TAAR1 3216/4885IDO1 3317/4885
US-20250255821-A1 SOLID DISPERSIONS COMPRISING A SGC STIMULATOR GMPS, PRKG1, GUCY1A2 LMNA 4083/4885TAAR1 3393/4885IDO1 3974/4885
US-20260103457-A1 NOVEL PROCESS FOR PREPARATION OF SOLUBLE GUANYLATE CYCLASE STIMULATORS GUCY1B1, GUCY1B2, GUCY1A2 LMNA 4037/4885TAAR1 2857/4885IDO1 3704/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.